Abstract: This invention relates to polymer particles, a process for their preparation, the use of these particles for the preparation of an electrophoretic device, electrophoretic displays comprising such particle, and new polymerizable dyes.
Type:
Grant
Filed:
November 25, 2015
Date of Patent:
July 9, 2019
Assignees:
Merck Patent GmbH, The Queen's University of Belfast
Inventors:
Jonathan Henry Wilson, Louise Diane Farrand, Anthony Lawrence, Sarah Youngs
Abstract: The present invention provides a compound of Formula (I) and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds and said stereoisomers, and pharmaceutical compositions thereof, and methods for using said compounds and compositions for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal media comprising them, and to the use of the polymerizable compounds and liquid crystalline media for optical, electro-optical and electronic purposes, in particular in liquid crystalline displays, especially in liquid crystalline displays of the polymer sustained alignment type.
Type:
Grant
Filed:
June 7, 2016
Date of Patent:
July 9, 2019
Assignee:
MERCK PATENT GMBH
Inventors:
Qiong Tong, Nico Schwebel, Constanze Brocke, Kaja Christina Deing, Julian Vogt, Elisabeth Meyer
Abstract: The present invention concerns the use of a combination consisting of D-aspartic and L-aspartic acids or L-aspartic acid used alone to stimulate the procreative activity in the man by increment of spermatozoon number and motility.
Abstract: The present invention relates to colored laser-markable and laser-weldable polymeric materials which are distinguished by the fact that they comprise, as absorber, at least one doped tin oxide or indium oxide having a large specific surface area.
Abstract: Disclosed are compounds of formula I the use of compounds of formula I in liquid crystal media and in particular to flexoelectric liquid crystal devices containing the liquid crystal media.
Abstract: The present invention relates to bi- and trinuclear metal complexes and to electronic devices, in particular organic electroluminescent devices, containing these complexes.
Type:
Application
Filed:
August 28, 2017
Publication date:
July 4, 2019
Applicant:
Merck Patent GmbH
Inventors:
Philipp Stoessel, Christian Ehrenreich, Philipp Harbach, Anna Hayer
Abstract: [Problem] To provide a composition, which is a reverse pattern formation composition comprising an aqueous solvent having little influence on a resist pattern, and which is excellent in flatness and filling properties after coating and has excellent etching resistance. Furthermore, a method for forming a pattern using the same is provided. [Means for Solution] A reverse pattern formation composition comprising a polysiloxane compound comprising a repeating unit having a nitrogen-containing group and a solvent comprising water, and a method for forming a fine pattern using the same.
Abstract: The application relates to a device for regulating the entry of light into a room, which comprises a switchable layer of specific design comprising a twisted nematic liquid-crystalline medium and a dichroic compound.
Type:
Grant
Filed:
September 22, 2014
Date of Patent:
July 2, 2019
Assignee:
MERCK PATENT GMBH
Inventors:
Michael Junge, Andreas Beyer, Ursula Patwal
Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
Type:
Grant
Filed:
January 12, 2018
Date of Patent:
July 2, 2019
Assignee:
MERCK & CIE
Inventors:
Rudolf Moser, Viola Groehn, Thomas Egger, Thomas Ammann
Abstract: Provided is a compound having formula (I): wherein R2 is selected from —C1, —Br and —CN; R1 and R4 are independently selected from H and —F; R631, R632, R641 and R642 are independently selected from —H, —F and substituted or unsubstituted C1-C3 alkyl groups; and R651 and R652 are independently selected from H and substituted or unsubstituted C1-C3 alkyl groups and substituted or unsubstituted phenyl groups; and wherein at least one of R631, R632, R641, R642 and R652 is not —H, or wherein when all of R631, R632, R641, R642 and R652 are —H, R651 is not Me or Et.
Abstract: The invention relates to novel organic semiconducting compounds, which are small molecules or conjugated polymers, containing one or more fluorinated polycyclic units, to methods for their preparation and educts or intermediates used therein, to compositions, polymer blends and formulations containing them, to the use of the compounds, compositions and polymer blends as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices, organic photodetectors (OPD), organic field effect transistors (OFET) and organic light emitting diodes (OLED), and to OE, OPV, OPD, OFET and OLED devices comprising these compounds, compositions or polymer blends.
Type:
Grant
Filed:
March 17, 2015
Date of Patent:
July 2, 2019
Assignee:
Merck Patent GmbH
Inventors:
Mansoor D'Lavari, William Mitchell, Changsheng Wang, David Sparrowe
Abstract: The present invention relates to methods of treating or preventing a viral infection using Compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Compound of Formula (I).
Abstract: The present invention provides novel peptide sequences for use in microbial transgluatminase-mediated, in particular mTG2-mediated bioconjugations, in particular for the manufacture of antibody-drug-conjugates. Further disclosed are bioconjugation methods employing mTG2 and the novel peptide sequence motifs of the invention. The present invention further provides proteins comprising the novel sequence motifs of the invention as well as polynucleotides encoding the same.
Type:
Application
Filed:
August 4, 2016
Publication date:
June 27, 2019
Applicant:
Merck Patent GmbH
Inventors:
Birgit Piater, Ulrich Betz, Harald Kolmar, Vanessa Siegmund
Abstract: Container system and method for freezing (and subsequently thawing) a liquid such as a drug substance, such that all containers in a set have a uniform width, hence uniform freeze-path length, in the widthwise direction and perpendicular to major walls of the containers, irrespective of the particular length, height, and volumetric capacity of the various containers in the set. This leads to uniform freezing performance and thereby reduces cryoconcentration. The system also eliminates or reduces ice-bridging, and the potential for containers rupturing during freezing and thawing operations.
Type:
Application
Filed:
August 21, 2017
Publication date:
June 27, 2019
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Jeffrey Charles JOHNSON, Anthony FLAMMINO, Mark Anton PETRICH, Scott MCFEATERS, John H. ROOSA, JR., Robert Ian ALPERN, Joseph W. LOCURCIO, Matthew H. FLAMM
Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae.
Type:
Application
Filed:
December 4, 2018
Publication date:
June 27, 2019
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
William J. Smith, Patrick McHugh, Michael Albert Winters, Julie M. Skinner, Jian He, Luwy Musey, Chitrananda Abeygunawardana, Yadong Adam Cui, Michael J. Kosinski
Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form using a 3D printing process as well. The process is a printing process that allows the production of solid pharmaceutical administration forms in a flexible manner and in conformity with the high quality standards required for the production of pharmaceuticals.
Type:
Application
Filed:
September 8, 2017
Publication date:
June 27, 2019
Applicant:
Merck Patent GmbH
Inventors:
Stefan SCHILLER, Andrea HANEFELD, Gerhard JONSCHKER
Abstract: The present invention relates inter alia to compositions comprising conjugated polymers and a small molecule, devices comprising the composition and the application of the devices.
Type:
Grant
Filed:
March 13, 2015
Date of Patent:
June 25, 2019
Assignee:
Merck Patent GmbH
Inventors:
Junyou Pan, Herwig Buchholz, Ludvig Edman, Shi Tang
Abstract: The present invention relates to pyrazolopyrimidine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.
Type:
Grant
Filed:
March 7, 2016
Date of Patent:
June 25, 2019
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Jongwon Lim, Michael D. Altman, Jason D. Brubaker, Craig R. Gibeau